Postal ballot also clears remuneration proposal and new ESOP 2026 scheme, strengthening the company’s leadership and talent retention strategy
Former Cipla MD & CEO to lead next phase of growth at science-led CDMO platform; Vivek Sharma transitions to advisory role
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
This strategic investment strengthens Cohance's integrated oligonucleotide platform
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
The change of name has been carried on pursuant to the Scheme of Amalgamation
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
